ToolsCalculators
Mekhail Extension of the Motzer Score
Extends the MSKCC/Motzer model with prior radiotherapy and metastatic site count for metastatic RCC.
Mekhail Extension of the Motzer Score
Time from diagnosis to treatment <1 year
LDH above the upper limit of normal
Hemoglobin below the lower limit of normal
Corrected serum calcium >10 mg/dL
Prior radiotherapy
≥2 sites of metastasis (e.g., lung, liver, retroperitoneal nodes)
Result0 factors
Favorable risk — median overall survival ~26.0 months.
- Risk group
- Favorable risk
- Median overall survival
- ~26.0 months
When to use
- Prognosticating previously untreated metastatic renal cell carcinoma using an expanded set of six clinical factors validated in an independent cohort.
Formula
Count of: time diagnosis-to-treatment <1y, elevated LDH, low hemoglobin, corrected calcium >10 mg/dL, prior radiotherapy, and ≥2 metastatic sites. Favorable 0-1 factors, intermediate 2, poor >2.
Pearls and pitfalls
- Extends the original 5-factor Motzer/MSKCC model; performance status was not retained as independent in this validation cohort, while prior radiotherapy and multi-site metastasis were added.